Patents by Inventor Scott Cowen

Scott Cowen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150119480
    Abstract: A one-component moisture curing composition expands and cures under ambient conditions without the use of external blowing agents. The one-component moisture cure foam contains (1) a moisture curing polymer, (2) anhydrous molecular sieves that are able to adsorb atmospheric moisture to release adsorbed gases, optionally (3) catalyst compound(s) to accelerate the reaction between atmospheric moisture and the polymer, and optionally (4) other additives such as surfactants, fillers, adhesion promoters, pigments, water scavengers and foamable additives.
    Type: Application
    Filed: October 28, 2013
    Publication date: April 30, 2015
    Applicant: Royal Adhesives & Sealants Canada Ltd.
    Inventors: Alexander Botrie, Yuan Deng, Scott Cowen
  • Publication number: 20100197749
    Abstract: The invention relates to chemical compounds of formula (I) and (II): or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: January 15, 2007
    Publication date: August 5, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Scott Cowen, Tracey Deegan, Gurmit Grewal, Vibha Oza, Jamal Carlos Saeh, Qibin Su
  • Publication number: 20080027060
    Abstract: N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.
    Type: Application
    Filed: August 7, 2007
    Publication date: January 31, 2008
    Inventors: Eva Altmann, Claudia Betschart, Keigo Gohda, Miyuki Horiuchi, Rene Lattmann, Martin Missbach, Junichi Sakaki, Michihiro Takai, Naoki Teno, Scott Cowen, Paul Greenspan, Leslie McQuire, Ruben Tommasi, John van Duzer
  • Publication number: 20050245525
    Abstract: Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.
    Type: Application
    Filed: April 27, 2005
    Publication date: November 3, 2005
    Inventors: Kathleen Keegan, Edward Kesicki, John Gaudino, Adam Cook, Scott Cowen, Laurence Burgess